Targeting angiogenesis in cancer therapy.

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for tumor growth, survival, and proliferation.
• First proposed in 1971, the concept of targeting angiogenesis has significantly impacted cancer research and therapeutic strategies.
• Despite decades of research and clinical application of antiangiogenic agents, the complex multistep process of angiogenesis remains incompletely understood.

Purpose of the Study:

• To review the key signaling pathways involved in tumor angiogenesis.
• To discuss antiangiogenic agents that have been approved or are under investigation for cancer therapy.
• To provide an updated overview of the field for researchers and clinicians.

Main Methods:

• Literature review of scientific publications on tumor angiogenesis.
• Analysis of signaling pathways regulating angiogenesis in cancer.
• Compilation of data on approved and investigational antiangiogenic agents.
• Focus on agents approved by the U.S. Food and Drug Administration (FDA) or in clinical trials.

Main Results:

• Identified critical signaling pathways, including VEGF, FGF, and angiopoietins, that drive tumor angiogenesis.
• Summarized the mechanisms of action for various antiangiogenic drugs.
• Highlighted the clinical success and limitations of current antiangiogenic therapies.
• Presented a comprehensive list of FDA-approved and investigational antiangiogenic agents.

Conclusions:

• Targeting tumor angiogenesis remains a promising strategy in cancer therapy.
• Further elucidation of complex angiogenesis pathways is needed for developing more effective treatments.
• Combination therapies involving antiangiogenic agents may overcome resistance and improve patient outcomes.
• Continued research into novel antiangiogenic agents and targets is essential for advancing cancer care.